Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Clinical trial NCT01945021 · COMPLETED
Trial details
- NCT number
- NCT01945021
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-30
- Primary completion
- 2015-07-31
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.